Development of a new tuberculosis vaccine: Is there value in the mucosal approach'

Immunotherapy

Volumn 6, Issue 9, 2014, Pages 1001-1013

  Diogo, Gil Reynolds ^a   Reljic, Rajko ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

adjuvants; BCG; immunity; lungs; mucosal; tuberculosis; vaccine

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; LIVE VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; BCG VACCINATION; DENDRITIC CELL; EFFECTOR CELL; HUMAN; HUMORAL IMMUNITY; INFECTION PREVENTION; LUNG ALVEOLUS MACROPHAGE; LUNG TUBERCULOSIS; MUCOSAL IMMUNITY; MYCOBACTERIUM BOVIS BCG; REVIEW; TUBERCULOSIS; ADULT; ANIMAL; IMMUNOLOGY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; RABBIT;

ADULT; ANIMALS; BCG VACCINE; HUMANS; IMMUNITY, MUCOSAL; MICE; MYCOBACTERIUM TUBERCULOSIS; RABBITS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT;

EID: 84908149679     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.62     Document Type: Review

References (108)

1. Beresford B, Sadoff JC. Update on research and development pipeline: tuberculosis vaccines. Clin. Infect. Dis. 50 (Suppl. 3), S178-S183 (2010
2. WHO. Tuberculosis Fact Sheet No. 104 (2012). www.who.int/mediacentre/factsheets/fs104/en/
3. Royce S, Grzemska M Treatment of tuberculosis guidelines (2012). http://whqlibdoc.who.int/publications/2010/9789241547833-eng.pdf'ua=1
4. Aagaard C, Dietrich J, Doherty M, Andersen P. TB vaccines: current status and future perspectives. Immunol. Cell Biol. 87(4), 279-286 (2009)
5. Smith JP. Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis. Yale J. Biol. Med. 84(4), 361-369 (2011
6. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv. Drug Deliv. Rev. 62(4-5), 394-407 (2010
7. Kaufmann SHE, Hussey G, Lambert P. New vaccines for tuberculosis. Lancet 375(9731), 2110-2119 (2010
8. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148-158 (2006
9. Li W, Deng G, Li M, Liu X, Wang Y. Roles of mucosal immunity against Mycobacterium tuberculosis infection. Tuberc. Res. Treatment 2012, 791728 (2012
10. Kraehenbuhl J, R Neutra M. Mucosal vaccines: where do we stand'. Curr. Top. Med. Chem. 13(20), 2609-2628 (2013
11. Czerkinsky C, Holmgren J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr. Top. Microbiol. Immunol. 354, 1-18 (2012
12. Woof JM, Mestecky J. Mucosal immunoglobulins. Immunol. Rev. 206(1), 64-82 (2005
13. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat. Rev. Immunol. 3(10), 822-829 (2003
14. Sigmundsdottir H, Butcher EC. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat. Immunol. 9(9), 981-987 (2008
15. Kleinnijenhuis J, Oosting M, Joosten LA, Netea MG, Van Crevel R. Innate immune recognition of Mycobacterium tuberculosis. Clin. Dev. Immunol. 2011, 405310 (2011
16. Bhatt K, Salgame P. Host innate immune response to Mycobacterium tuberculosis. J. Clin. Immunol. 27(4), 347-362 (2007
17. Akira S, Tokeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2(8), 675-680 (2001
18. Korbel DS, Schneider BE, Schaible UE. Innate immunity in tuberculosis: myths and truth. Microb. Infect. 10(9), 995-1004 (2008
19. Rescigno M, Urbano M, Valzasina B et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2(4), 361-367 (2001
20. Fagarasan S, Kawamoto S, Kanagawa O, Suzuki K Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis. Annu. Rev. Immunol. 28, 243-273 (2009
21. Mayer L, Shao L. Therapeutic potential of oral tolerance. Nat. Rev. Immunol. 4(6), 407-419 (2004
22. Itano AA, Jenkins MK. Antigen presentation to naive CD4 T cells in the lymph node. Nat. Immunol. 4(8), 733-739 (2003
23. Masten BJ, Lipscomb MF. Comparison of lung dendritic cells and B cells in stimulating naive antigen-specific T cells. J. Immunol. 162(3), 1310-1317 (1999
24. von Garnier C, Filgueira L, Wikstrom M et al. Anatomical location determines the distribution and function of dendritic cells and other APCs in the respiratory tract. J. Immunol. 175(3), 1609-1618 (2005
25. Bodnar KA, Serbina NV, Flynn JL. Fate of Mycobacterium tuberculosis within murine dendritic cells. Infect. Immun. 69(2), 800-809 (2001
26. Gonzalez-Juarrero M, Orme IM. Characterization of murine lung dendritic cells infected with Mycobacterium tuberculosis. Infect. Immun. 69(2), 1127-1133 (2001
27. Giacomini E, Iona E, Ferroni L et al. Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response. J. Immunol. 166(12), 7033-7041 (2001
28. Tamura S, Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J. Infect. Dis. 57(6), 236-247 (2004
29. Kiyono H, Fukuyama S. NALT-versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol.4(9), 699-710 (2004
30. Brandtzaeg P, Farstad IN, Haraldsen G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol. Today 20(6), 267-277 (1999
31. Ogra PL. Mucosal immunity: some historical perspective on host-pathogen interactions and implications for mucosal vaccines. Immunol. Cell Biol. 81(1), 23-33 (2003
32. Neutra M, Kraehenbuhl J. Cellular and molecular basis for antigen transport across epethilial barriers. In: Mucosal Immunology. Mestecky J, Lamm ME, McGhee JE, Bienenstock J, Mayer L, Strober W (Eds). Academic Press, New York, 111-118 (2005
33. Kraehenbuhl J, Neutra MR. Epithelial M cells: differentiation and function. Annu. Rev. Cell Dev. Biol. 16(1), 301-332 (2000
34. Kim DY, Sato A, Fukuyama S et al. The airway antigen sampling system: respiratory M cells as an alternative gateway for inhaled antigens. J. Immunol. 186(7), 4253-4262 (2011
35. Van Crevel R, Ottenhoff TH, Van Der Meer JW. Innate immunity to Mycobacterium tuberculosis. Clin. Microbiol. Rev. 15(2), 294-309 (2002
36. Mazzaccaro RJ, Gedde M, Jensen ER et al. Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA 93(21), 11786-11791 (1996
37. Costello AM, Kumar A, Narayan V et al. Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis'. Trans. R. Soc. Trop. Med. Hyg. 86(6), 686-692 (1992
38. Sanchez-Rodriguez C, Estrada-Chavez C, Garcia-Vigil J et al. An IgG antibody response to the antigen 85 complex is associated with good outcome in Mexican Totonaca Indians with pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 6(8), 706-712 (2002
39. Vordermeier H, Venkataprasad N, Harris D, Ivanyi J. Increase of tuberculous infection in the organs of B cell'deficient mice. Clin. Exp. Immunol. 106(2), 312-316 (1996
40. Rodríguez A, Tjärnlund A, Ivanji J et al. Role of IgA in the defense against respiratory infections: IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine 23(20), 2565-2572 (2005
41. Kozakiewicz L, Phuah J, Flynn J, Chan J. The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Adv. Exp. Med. Biol. 783, 225-250 (2013
42. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Natl Acad. Sci. 89(15), 6901-6905 (1992
43. Mestecky J, Russell MW, Elson CO. Intestinal IgA: novel views on its function in the defence of the largest mucosal surface. Gut 44(1), 2-5 (1999
44. Doreau A, Belot A, Bastid J et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol. 10(7), 778-785 (2009
45. Balu S, Reljic R, Lewis MJ et al. A novel human IgA monoclonal antibody protects against tuberculosis. J. Immunol. 186(5), 3113-3119 (2011
46. Reljic R, Williams A, Ivanyi J. Mucosal immunotherapy of tuberculosis: is there a value in passive IgA?. Tuberculosis 86(3), 179-190 (2006
47. Ogra PL, Mucosal immunity: some historical perspective on host-pathogen interactions and implications for mucosal vaccines. Immunol. Cell Biol. 81, 23-33 (2003
48. Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. Nat. Rev. Immunol. 5(10), 819-826 (2005
49. Wolf AJ, Desvignes L, Linas B et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med. 205(1), 105-115 (2008
50. Reiley WW, Calayag MD, Wittmer ST et al. ESAT-6- specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc. Natl Acad. Sci. USA 105(31), 10961-10966 (2008
51. Van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30(12), 3689-3698 (2000
52. Khader SA, Bell GK, Pearl JE et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4 T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8(4), 369-377 (2007
53. Chackerian A, Alt J, Perera V, Behar SM. Activation of NKT cells protects mice from tuberculosis. Infect. Immun. 70(11), 6302-6309 (2002
54. Schluger NW, Rom WN. The host immune response to tuberculosis. Am. J. Respir. Crit. Care Med. 157(3), 679-691 (1998
55. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11, S45-S53 (2005
56. Mowat A, Faria A, Weiner H. Oral tolerance: physiologic basis and clinical applications. In: Mucosal Immunology. Ogra, PL, Mestecky J, Lamin ME, Strober W, Bienenstock JM, McGhee JR, Mayer L (Eds). Academic Press, CA, USA (1999
57. Reyes V, Ye G, Ogra P, Garofalo R. Antigen presentation of mucosal pathogens: the players and the rules. Int. Arch. Allergy Immunol. 112(2), 103-114 (1997
58. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14(2), 430-445 (2001
59. Bull CG, McKee C. Respiratory immunity in rabbits. VII. Resistance to intranasal infection in the absence of demonstrable antibodies. Am. J. Epidemiol. 9(2), 490-499 (1929
60. Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF. Efficient induction of mucosal and systemic immune responses by virus?like particles administered intranasally: implications for vaccine design. Eur. J. Immunol. 38(1), 114-126 (2008
61. Shim B, Choi YK, Yun C et al. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS ONE 6(11), e27953 (2011
62. Mora JR, Iwata M, Eksteen B et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 314(5802), 1157-1160 (2006
63. MacPherson G, Liu L. Dendritic cells and Langerhans cells in the uptake of mucosal antigens. Curr. Top. Microbiol. Immunol. 236, 33-53 (1999
64. Macpherson A, McCoy K, Johansen F, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol. 1(1), 11-22 (2008
65. Mitragotri S. Immunization without needles. Nat. Rev. Immunol. 5(12), 905-916 (2005
66. Ballester M, Nembrini C, Dhar N et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 29(40), 6959-6966 (2011
67. Jensen K, Ranganathan UD, Van Rompay KK et al. A recombinant attenuated Mycobacterium tuberculosis vaccine strain is safe in immunosuppressed simian immunodeficiency virus-infected infant macaques. Clin. Vaccine Immunol. 19(8), 1170-1181 (2012
68. Duerr A. Update on mucosal HIV vaccine vectors. Curr. Opin. HIV AIDS 5(5), 397-403 (2010
69. Sack DA, Shimko J, Torres O et al. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 25(22), 4392-4400 (2007
70. Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat. Rev. Microbiol. 5(7), 540-553 (2007
71. Davis S. Nasal vaccines. Adv. Drug Deliv. Rev. 51(1), 21-42 (2001
72. Fine PE. BCG: the challenge continues. Scand. J. Infect. Dis. 33(4), 243-245 (2001
73. Hesseling AC, Marais BJ, Gie RP et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25(1), 14-18 (2007
74. Hesseling A, Johnson L, Jaspan H et al. Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants. . Bull. World Health Organ. 87(7), 505-511 (2009
75. Watanabe K, Matsubara A, Kawano M et al. Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization. Vaccine 32(15), 1727-1735 (2014
76. White AD, Sibley L, Dennis MJ et al. Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques. Clin. Vaccine Immunol. 20(5), 663-672 (2013
77. Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173(10), 6357-6365 (2004
78. Hoft DF, Blazevic A, Stanley J et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 30(12), 2098-2108 (2012
79. Abel B, Tameris M, Mansoor N et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am. J. Respir. Crit. Care Med. 181(12), 1407-1417 (2010
80. Stylianou E, Diogo GR, Pepponi I et al. Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice. Eur. J. Immunol. 44(2), 440-449 (2013
81. Reljic R, Sibley L, Huang JM et al. Mucosal vaccination against tuberculosis using inert bioparticles. Infect. Immun. 81(11), 4071-4080 (2013
82. Pepponi I, Diogo GR, Stylianou E et al. Plant-derived recombinant immune complexes as self-adjuvanting TB immunogens for mucosal boosting of BCG. Plant Biotechnol. J. 12(7), 840-850 (2014
83. Doherty TM, Olsen AW, Van Pinxteren L, Andersen P. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 70(6), 3111-3121 (2002
84. Haile M, Schröder U, Hamasur B et al. Immunization with heat-killed Mycobacterium bovis Bacille Calmette- Guerin (BCG) in Eurocine? L3 adjuvant protects against tuberculosis. Vaccine 22(11), 1498-1508 (2004
85. Santosuosso M, Zhang X, McCormick S, Wang J, Hitt M, Xing Z. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J. Immunol. 174(12), 7986-7994 (2005
86. Xing Z, Lichty BD. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis 86(3), 211-217 (2006
87. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171(3), 1602-1609 (2003
88. McShane H, Pathan AA, Sander CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10(11), 1240-1244 (2004
89. Tameris MD, Hatherill M, Landry BS et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled Phase 2b trial. Lancet 381(9871), 1021-1028 (2013
90. Takahashi H, Sasaki K, Takahashi M et al. Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4 and CD8 T cells to nasal killed-bacillus Calmette-Guerin in mice. Vaccine 24(17), 3591-3598 (2006
91. Flynn JAL, Chan J. Immunology of tuberculosis. Annu. Rev. Immunol. 19(1), 93-129 (2001
92. Ohara N, Nishiyama T, Ohara-Wada N, Matsumoto S, Matsuo T, Yamada T. Characterization of the transcriptional initiation regions of genes for the major secreted protein antigens 85C and MPB51 of Mycobacterium bovis BCG. Microb. Pathog. 23(5), 303-310 (1997
93. Macadam A, Arnold C, Howlett J et al. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 172(2), 408-414 (1989
94. Todoroff J, Lemaire MM, Fillee C et al. Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice. PLoS ONE 8(5), e63344 (2013
95. Olsen AW, Van Pinxteren LAH, Okkels LM, Rasmussen PB, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect. Immun. 69(5), 2773-2778 (2001
96. Holmgren J, Svennerholm A. Vaccines against mucosal infections. Curr. Opin. Immunol. 24(3), 343-353 (2012
97. Betancourt AA, Delgado C, Estévez ZC et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int. J. Infect. Dis. 11(5), 394-401 (2007
98. Zhu Q, Talton J, Zhang G et al. Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat. Med. 18(8), 1291-1296 (2012
99. Eyles J, Bramwell V, Singh J, Williamson E, Alpar H. Stimulation of spleen cells in vitro by nanospheric particles containing antigen. J. Control. Release 86(1), 25-32 (2003
100. Eyles J, Bramwell V, Williamson E, Alpar H. Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. Vaccine 19(32), 4732-4742 (2001
101. Carpenter ZK, Williamson ED, Eyles JE. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu. J. Control. Release 104(1), 67-77 (2005
102. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Curr. Opin. Immunol. 22(3), 411-416 (2010
103. Holmgren J, Adamsson J, Anjuère F et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett. 97(2), 181-188 (2005
104. Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24(33), 5937-5949 (2006
105. Shimizu T, Sasaki K, Kato M et al. Induction of thymus-derived gammadelta T cells by Escherichia coli enterotoxin b subunit in peritoneal cavities of mice. Clin. Diagn. Lab. Immunol. 12(1), 157-164 (2005
106. Chong CSW, Cao M, Wong WW et al. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J. Control. Release 102(1), 85-99 (2005
107. Haile M, Hamasur B, Jaxmar T et al. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. Tuberculosis 85(1), 107-114 (2005
108. Yoon HA, Aleyas AG, George JA et al. Modulation of immune responses induced by DNA vaccine expressing glycoprotein B of pseudorabies virus via coadministration of IFN-?-associated cytokines. J. Interferon Cytokine Res. 26(10), 730-738 (2006